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B. J. Kullberg
Fungal infections are the primary cause of mortality in patients with severely impaired 
host defense mechanisms, such as neutropenic patients with acute Jeukemia or those 
who have undergone bone marrow transplantation. In view of the unacceptably high 
mortality due to disseminated candidiasis, it is rational to focus on augmentation of 
host defense mechanisms in addition to conventional antifungal therapy. In vitro, a va­
riety of immunomodulators, including tumor necrosis factor, interferon-g, and the 
hematopoietic growth factors, enhance the killing of Candida albicans, Aspergillus 
fumigatus, and Cryptococcus neoformans. Various studies have demonstrated benefi-
»
cial effects of immunomodulatory therapy in animal models of disseminated candidi­
asis. For further preclintcal and clinical studies, recombinant interferon-g, interleukin-1, 
granulocyte colony-stimulating factor, and the other hematopoietic growth factors are 
currently the most promising immunomodulators.
Recently, a variety of agents have been investigat­
ed as potential immunomodulators in the treat­
ment of sepsis syndrome. They include: antibod­
ies to bacterial lipopolysaccharide (LPS) and to 
cytokines, recombinant cytokines as well as 
cytokine antagonists, monoclonal antibodies to the 
integrin family, and modulators of the coagulation 
cascade. Although it may be tempting to apply a 
similar concept to the immunomodulation of dis­
seminated fungal infections, e.g., candidemia, the 
important pathophysiological differences be­
tween disseminated bacterial infection and dissem­
inated fungal infection must be taken into consid­
eration. Experimental gram-negative infection in 
animal models leads to high concentrations of pro- 
inflammatory cytokines such as tumor necrosis 
factor-a (TNF-a) and interleukin-lB (IL-1B). 
Specific inhibitors of either TNF-a or interleukin-
1 (IL-1) effectively prevent mortality in these 
models, underscoring the important role of pro- 
inflammatory cytokines in the pathogenesis of le­
thal sepsis (1).
In a similar model of lethal infection of experimen­
tal animals with Candida albicans, only very low 
and gradually increasing concentrations of pro- 
inflammatory cytokines were found, and treatment
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with cytokine inhibitors or antagonists did not in­
fluence the outcome of candidemia, indicating that 
these animals did not die from cytokinemia (2 ,3). 
Apparently, the concept of lethal cytokinemia, 
which is pivotal in the design of trials for sepsis 
syndrome, does not apply to candidemia. A l­
though candidemia presenting as fulminant sepsis 
has been described in a minority of patients, no 
data exist on cytokine patterns in this group. It may 
be that other factors such as underlying disease 
contribute to the activation of the cytokine net­
work in this specific subgroup, leading to further 
production and release of pro-inflammatory cyto­
kines upon subsequent challenge with Candida  
albicans.
In contrast, the administration of monoclonal an­
tibodies to TNF-a leads to increased mortality in 
models of disseminated candidiasis and to in­
creased outgrowth of Candida albicans com­
pared to that seen in controls (2,4). The effect of 
anti-TNF-a is not seen in neutropenic animals, 
which supports observations indicating that in 
vitro TNF-a is required to activate polymorpho­
nuclear leukocytes (PMNs) for killing of Candida  
spp. and that its inhibition restricts the intracellu­
lar killing of the yeasts. Therefore, it will prove 
more productive to direct immunotherapy to­
ward enhancing host defense mechanisms by 
increasing the numbers of phagocytic cells, m od­
ulating the kinetics of these cells at the site of in-
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Table 1: Antifunga! effects of selected cytokines and hematoppoietic growth factors in vitro and in animal models.
Cytokine/ Candida spp. Aspergillus spp. Cryptococcus spp.
growth factor In vitro In vivo In vitro In vivo In vitro In vivo
TNF-a + + NA NA + +
IFN-7 + + + + + +
IL-1 no effect + NA NA NA NA
G-CSF + + + + + +
GM-CSF + + + NA + NA
M-CSF + + NA NA + NA
G-CSF, granuJocye colony-stimulating factor; GM-CSF, granulocyte macrophage colony-stimulating factor; IFN-7 , Interferon-7 ; IL-1, interleukin 
1; M-CSF, macrophage colony-stimulating factor; NA, no data availabe; TNF-a, tumor necrosis factor-a; +, Beneficial effect has been demon­
strated on killing in vitro or on course of infection in animal model.
fection, or activating phagocytes to kill the path­
ogenic fungal organisms more effectively (Table 
1). These effects may be partly controlled by the 
differentiation of T-helper cell subsets. 
The TH1/TH2 balance itself may be the target of 
immunotherapy as well. Other potential targets 
might include modulating humoral fungicidal 
factors, the interaction between circulating fungal 
pathogens and endothelial cells, and factors that 
affect either the pharmacokinetics or the pharma­
codynamics of antifungal agents. The nature and 
stage of the infection determine the type of effec­
tor cells that therapy should target (reviewed in
5). Alveolar macrophages provide the first line of 
host defense against airborne infection with 
Aspergillus conidia, and activation of these cells 
may be considered a preventive measure. After 
Aspergillus germinates and the hyphae invade 
the pulmonary tissue, PMNs become the main ef­
fector cells involved, killing the mycelia of 
Aspergillus by secreting oxidative and nonoxida- 
tive metabolites. Therefore, immunotherapy at 
this stage of the disease should focus on either the 
number or the function of PMNs.
Invasive cryptococcosis is strongly associated 
with disorders of lymphocyte function, such as 
AIDS, since T-cell specific immunity is the most 
important host defense mechanism against 
Cryptococcus neoformans. Depletion of natural 
killer cells does not affect the course of experimen­
tal cryptococcosis or the load of Cryptococcus 
neoformans in the organs except for the lungs, in­
dicating that natural killer cells play a limited and 
early role in the host defense to Cryptococcus 
neoformans in the lung. However, in the early 
phase of the infection, before cell-mediated immu­
nity is activated, macrophages and PMNs also play 
a role in host defense to these yeasts; immunother­
apy could focus on these defense mechanisms as 
well.
In candidiasis, the clinical manifestation of the dis­
ease is crucial in establishing which host defense
mechanism should be addressed. Whereas T-cell- 
mediated immunity is involved in candidiasis of 
the mucosal surfaces, PMNs play the primary role 
in host defense against invasive or disseminated 
candidiasis, as demonstrated by the various patient 
groups at risk for these infections. Disseminated 
candidiasis is relatively rare in patients with 
AIDS and other diseases affecting T-cell function, 
which suggests that cell-mediated immunity is of 
minor importance in the host defense against this 
form of infection. It is generally accepted that 
PMNs should be the primary object of strategies 
to enhance host defenses against candidemia and 
acute disseminated or invasive disease. In chron­
ic disseminated candidiasis or mucosal infection, 
efforts at enhancing host defenses should include 
activation of macrophages and modulation of 
T-helper cell differentiation.
Pro-Inflammatory Cytokines
Interferon-7  (IFN-7 ) has been shown to be an es­
sential cytokine for activating fungicidal activities 
of phagocytes in vitro (6,7). Administration of a 
single dose of recombinant IFN-7 to mice with dis­
seminated candidiasis significantly reduced the 
outgrowth of Candida albicans in their organs, 
even when the infection had been established for 
several days (8). Of note, a single injection of IFN-
7  resulted in a beneficial effect that persisted for 
at least one week. These data indicate that it 
might be feasible to study combination therapy of 
a conventional antifungal agent and^ecombinant 
IFN-7 in treating disseminated candidiasis. In se­
verely neutropenic mice, treatment with IFN-7 did 
not alter the course of disseminated candidiasis, 
suggesting that the effect of IFN-7  is mediated 
through the activation of PMN (8). This is in 
agreement with the observation that neutrophils 
isolated from IFN-7 -treated mice show enhanced 
intracellular killing of Candida albicans (8). A re­
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cent study showed that administering recombinant 
IFN -7 has a beneficial effect on the course of le­
thal disseminated cryptococcosis in rats (9). A l­
though no specific clinical trials have been per­
formed to establish the role of recombinant IFN-
7 in the treatment of invasive mycoses, a 
beneficial effect of IFN-7 has been demonstrated 
in patients with chronic granulomatous disease, a 
rare specific disorder of phagocytes. In a large, 
prospective, randomized, placebo-controlled trial, 
the incidence of invasive aspergillosis in a group 
of patients with chronic granulomatous disease 
who received IFN-7 prophylaxis was significant­
ly reduced from 24 to 4% in two years, and PMNs 
from IFN-7-treated patients displayed enhanced 
killing of Aspergillus in vitro (10, 11). Taken to ­
gether, addition of IFN-7 to the antifungal regi­
men appears to be effective in treating infections 
with Candida, Cryptococcus ox Aspergillus spp. in 
non-neutropenic patients. Further prospective 
randomized clinical studies should be considered 
in these patient groups.
Recently, recombinant IL-1 has been adminis­
tered to patients in order to promote the hem at­
opoietic response after bone marrow transplanta­
tion (12,13). Although this cytokine has consider­
able side effects, such as fever, chills, and 
hypotension, clinical studies evaluating the specif­
ic effect of IL-1 on the host defense against 
Candida infection may be warranted. In an exper­
imental model it has been demonstrated that a sin­
gle injection of either recombinant interleukin l a  
(IL -la) or interleukin Ip  (IL-ip) protects neu tro­
penic mice from lethal disseminated candidiasis
(14). Treatment also significantly decreases the 
numbers of Candida albicans in the kidneys and 
spleen of infected normal mice and of mice ren­
dered immunocompromised by cyclophospha­
mide, hydrocortisone acetate, or total body irradi­
ation (15). A  similar protective effect of IL-1 has 
been demonstrated in models of bacterial infec­
tion caused by a variety of species (reviewed in 
16). Although the mechanism of IL-1 induced pro­
tection has not been fully elucidated, modulation 
of cytokine receptors and induction of acute 
phase proteins and other humoral factors contrib­
ute to its effect (16,17), which is independent of 
the presence or activation of phagocytic cells
(15).
Interleukin-12 (IL-12) is produced very early in 
the  infective process, upon antigen presentation by 
macrophages, and it enhances both the production 
o f  IFN -7 and T-cell differentiation. In a recent 
study recombinant IL-12 was administered to
rats with disseminated cryptococcosis (18). After 
two weeks of infection, treatment with either 
IL-12 or fluconazole reduced the outgrowth of or­
ganisms in the brain, and the combination of IL- 
12 and fluconazole had an additive effect. In the 
liver fluconazole failed completely to contain the 
infection, whereas treatment with IL-12 was effec­
tive in reducing the outgrowth of Cryptococcus 
neoformans (18).
Anti-Inflammatory Cytokines
The release of IFN-7 and the activation of mac­
rophages are both inhibited by anti-inflammato- 
ry cytokines such as interleukin-4 (IL-4) and in­
terleukin-10 (IL-10). Failure to clear a subacute or 
chronic infection with Candida albicans corre­
sponds with sustained production of IL-4 and IL- 
10 in susceptible mouse strains, whereas so-called 
constitutively resistant strains produce signifi­
cantly less IL-4 and IL-10 (19). Neutralization of 
either of these cytokines by specific monoclonal 
antibodies augments host resistance, leads to in­
creased survival of infected mice, and enhances the 
ability of their macrophages to kill Candida 
albicans in vitro (19,20). In a different approach, 
recombinant soluble receptors to IL-4 (sIL-4R) 
have been cloned (21).The sIL-4R circulate in the 
bloodstream and are able to bind and neutralize 
circulating IL-4. Treatment of mice with recombi­
nant sIL~4R was able to cure potentially lethal 
subacute disseminated infection caused by 
Candida albicans (21).
Hematopoietic Growth Factors
Colony-stimulating factor (CSF) is able to aug­
ment the numbers of circulating phagocytes and 
their precursors in the bone marrow (22), There- 
fore, granulocyte colony-stimulating factor 
(G-CSF) is now being administered to donors in 
order to elicit neutrophils that can be transfused 
into patients with life-threatening fungal infections 
(unpublished data). Moreover, CSF has been 
shown to enhance activation of the fungicidal ca­
pacity of phagocytic cells in vitro. Incubation of 
macrophages with macrophage colony-stimulating 
factor (M'CSF) enhances the killing of Candida 
spp. and Cryptococcus spp. (23,24). Treatment of 
chronic disseminated candidiasis in rats with M- 
CSF has been shown to reduce the outgrowth of 
Candida albicans (25). Neutrophil function is en­
hanced by G-CSF and granulocyte macrophage
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colony-stimulating factor (GM-CSF), and incuba­
tion of PMNs with either growth factor leads to 
increased killing of Candida spp. or Aspergillus 
spp. in vitro (7, 26). In an experimental model in 
vitro, the ability of PMNs to damage Aspergillus 
hyphae was abrogated by incubating the cells 
with corticosteroids, underscoring the fact that 
steroids are a risk factor for invasive aspergillosis 
(27). Incubating PMNs with G-CSF effectively re ­
versed the deleterious effect of steroids in this 
model, reinstating their capacity to kill 
Aspergillus in vitro (27). Incubating PMNs with 
IFN-y or the combination of G-CSF and IFN-y 
had similar effects (28). A  pilot study is therefore 
being conducted in the USA on the treatment of 
patients with proven aspergillosis with the combi­
nation of recombinant G-CSF and IFN-y. Other 
studies have shown that PMNs isolated from 
AIDS patients are less able to kill bacterial 
pathogens as well as Candida albicans in vitro (28). 
Administering a single dose of recombinant 
G-CSF to AIDS patients effectively restored the 
capacity of their peripheral blood PMNs to kill 
Candida albicans to normal levels (29).
In animal models of disseminated candidiasis, 
various studies have shown a beneficial effect of 
recombinant G-CSF given prophylactically. R e­
peated administration of G-CSF effectively pre­
vents the development of cyclophosphamide- 
induced neutropenia and protects animals after a 
lethal challenge with Candida albicans (30). Few­
er data exist on the therapeutic administration of 
G-CSF after the microorganisms have disseminat­
ed and the experimental infection has become es­
tablished. No effect of G-CSF was found in a 
carefully designed model of chronic disseminated 
candidiasis in persistently neutropenic rabbits 
(D. Arenberg et al., General Meeting of the 
American Society for Microbiology, Washington 
DC, 1990, Abstract no. F90). In contrast, in non- 
neutropenic animals, G-CSF was shown to be ef­
fective even when administration was begun aft­
er infection (31). Moreover, combination therapy 
of recombinant G-CSF with various antifungal 
agents appeared to be synergistic. A  multicenter, 
double-blind, randomized phase II trial is current­
ly being conducted in Europe to assess the safety 
and preliminary efficacy of G-CSF in combination 
with fluconazole in treating invasive candidiasis 
and candidemia in non-neutropenic patients.
I
Future Directions
In conclusion, the administration of recombinant 
G-CSF or the combination of G-CSF and IFN-y
in addition to conventional antifungal therapy 
currently comes closest to realizing the goals in the 
immunotherapy of invasive fungal infections, 
Various issues are to be addressed in the near fu­
ture: (i) following the ongoing phase II trial of 
G-CSF in disseminated candidiasis, clinical trials 
may be designed to investigate the use of G-CSF 
or the combination of G-CSF and IFN-y *n dis­
seminated candidiasis or invasive aspergillosis in 
non-neutropenic as well as neutropenic cancer pa­
tients; (ii) additional preclinical studies should ad­
dress the effects of recombinant GM-CSF and 
M-CSF when given as a therapeutic modality in 
animal models of candidiasis and aspergillosis, and 
clinical studies may be designed to address this 
purpose as well; (iii) clinical studies with recom­
binant IFN-y administered for prophylaxis or 
treatment of either candidiasis or aspergillosis in 
non-neutropenic subjects are warranted; (iv) a 
clinical trial to evaluate the ability of recombinant 
IL-1 to prevent fungal infections in either neutro­
penic or non-neutropenic patients at risk may be 
considered; and (v) more preclinical data are re­
quired on the effects of recombinant IL-1 and 
IFN-y in invasive aspergillosis.
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